Legend Biotech Corp
NASDAQ:LEGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.42
69.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Legend Biotech Corp
Legend Biotech Corp
Other Long-Term Assets
Legend Biotech Corp
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Legend Biotech Corp
NASDAQ:LEGN
|
Other Long-Term Assets
$156.8m
|
CAGR 3-Years
128%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$8.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
44%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$7.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
23%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$10.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
43%
|
CAGR 10-Years
21%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$3.2B
|
CAGR 3-Years
49%
|
CAGR 5-Years
17%
|
CAGR 10-Years
95%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
70%
|
CAGR 5-Years
34%
|
CAGR 10-Years
31%
|
|
Legend Biotech Corp
Glance View
Legend Biotech Corp. is a pioneering biotechnology company that has made significant strides in the field of cell therapy, particularly with its innovative approaches to treating cancer. Founded in 2014 and based in Somerset, New Jersey, Legend is at the forefront of developing advanced therapies that harness the power of the immune system. At the heart of its mission is its flagship product, a revolutionary chimeric antigen receptor T-cell (CAR-T) therapy aimed at targeting and eliminating cancer cells. Following promising clinical results, the company has attracted attention from investors looking for high-growth opportunities in the ever-evolving biotech landscape. With strategic partnerships, including a noteworthy collaboration with Johnson & Johnson's Janssen division, Legend is set to leverage substantial resources towards the commercialization of its therapies. For potential investors, Legend Biotech represents both opportunity and risk, typical of the biotechnology sector. The company operates in a competitive market but has positioned itself with a promising pipeline and a robust intellectual property portfolio that supports its growth initiatives. Its focus on personalized medicine not only aligns with current healthcare trends but also offers the potential for high returns, especially as the demand for effective cancer treatments continues to rise. As Legend progresses through clinical trials and moves towards regulatory approvals, investors will be keenly watching its developments, as successful outcomes could significantly enhance its market position and drive its stock value upward.
See Also
What is Legend Biotech Corp's Other Long-Term Assets?
Other Long-Term Assets
156.8m
USD
Based on the financial report for Dec 31, 2023, Legend Biotech Corp's Other Long-Term Assets amounts to 156.8m USD.
What is Legend Biotech Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
18%
Over the last year, the Other Long-Term Assets growth was 135%. The average annual Other Long-Term Assets growth rates for Legend Biotech Corp have been 128% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
